Barclays
BBIO icon

Barclays’s BridgeBio Pharma BBIO Stock Holding History

Barclays’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$928K – 4876
2024
Q1 		$928K Buy
+30,000
New +$1.02M ﹤0.01% 3171
2023
Q2 		– Sell
-2,100
Closed -$34.8K – 4565
2023
Q1 		$34.8K Buy
+2,100
New +$24.5K ﹤0.01% 4531

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Barclays's BBIO Position: Q2 2026 in Review

Barclays increased its BridgeBio Pharma (BBIO) stake by 69% in Q2 2026, buying an estimated $20.3M and bringing the position to 714,423 shares worth $53.2M. The position accounts for 0.01% of the portfolio, ranked #710.

Barclays first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Barclays held 714,423 shares of BridgeBio Pharma worth $53.2M as of Q2 2026.
  • Barclays bought 290,535 BridgeBio Pharma shares in Q2 2026, an estimated $20.3M.
  • BridgeBio Pharma made up 0.01% of Barclays's portfolio in Q2 2026, its #710 holding.
  • Barclays first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.